Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 221
  • Home
  • Print this page
  • Email this page
Year : 2016  |  Volume : 21  |  Issue : 1  |  Page : 56

Evaluation effects of nebulized gentamicin in exacerbation of chronic obstructive lung disease

1 Department of Pulmonary Medicine, Shahrekord University of Medical Sciences, Shahrekord; Department of Pulmonary Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 Social Health Determinants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
3 Department of Infectious Diseases, Shahrekord University of Medical Sciences, Shahrekord, Iran
4 Bamdad Respiratory and Sleep Research Center, Isfahan, Iran
5 Department of Internal Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Shahrekord, Iran

Correspondence Address:
Shahin Asgari-Savadjani
Department of Internal Medicine, Hajar Hospital, Shahrekord University of Medical Sciences, Varzesh Street, Shahrekord
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1735-1995.187278

Clinical trial registration IRCT2015081723659N1

Rights and Permissions

Background: Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world. Exacerbation of COPD has negative effect on quality of life. Therapeutic effect of nebulized antibiotics in pulmonary infections has been reported previously. Hence, we evaluated the effect of nebulized gentamicin in acute exacerbation of COPD (AECOPD). Materials and Methods: In this clinical trial study, 86 hospitalized patients with AECOPD were divided into two groups for using nebulized gentamicin twice daily (case group) and placebo (control group) for 5 days in addition to standard treatment. On admission and on the 6 th day, respiratory rate (RR), white blood cell (WBC), spirometry, and  SPO2 (arterial O2 saturation by pulse oxymetry) were measured in groups. The severity of dyspnea was evaluated by the Medical Research Council scale. Results: In both groups, changes of SpO 2 , RR, forced an expiratory volume of first second (FEV1), and forced vital capacity (FVC) were significant during the times of intervention (P < 0.05). However, changes of FEV1 and FVC were significantly different between two groups (P < 0.05). So that increments of FEV1 and FVC were higher in the case group than control group. WBC decreased significantly in the case group (P < 0.05) compared to control group. There was no significant difference between groups in severity of dyspnea after intervention (P > 0.05). Conclusion: Treatment with Nebulized Gentamicin in AECOPD exacerbation resulted in further improvement of FVC and FEV1 on the 6 th day.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded169    
    Comments [Add]    
    Cited by others 6    

Recommend this journal